AllSight
Companies · RGNX · Biological Products, (No Diagnostic Substances)

REGENXBIO Inc. (RGNX)

REGENXBIO Inc. (RGNX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

REGENXBIO Inc. (RGNX) stock — financials & valuation

Key numbers for REGENXBIO Inc. (RGNX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 41/100 — a percentile rank of REGENXBIO Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$489.8M
P / S2.8×
EV / EBITDA-3.0×
Gross margin86.4%
Operating margin-94.1%
Net margin-112.6%
Return on equity-273.7%
ROIC-465.3%
Revenue growth12.0%
Debt / equity0.0×
Dividend yield0.0%

Is REGENXBIO Inc. overvalued? P/S looks undervalued vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from REGENXBIO Inc.’s own financial statements and shown as context, never as advice.

Sep 23, 2026$39M patent settlement
REGENXBIO settles ELEVIDYS patent case for $39M, giving up future AAVrh74 claims
Aug 25, 2026Board reshuffle
REGENXBIO reshuffles board, adding investor Greg Ciongoli as two directors retire
Aug 24, 2026BLA delay
REGENXBIO’s RGX-121 hits a new FDA hold, derailing near-term BLA hopes
Aug 6, 2026
Clinical execution and FDA clarity strengthen the catalyst path, despite one-time earnings
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact